Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease
Claire L. Langrish(Principia Biopharma (United States)), Philip A. Nunn(Principia Biopharma (United States))
Cited by 121
Related Papers
Open trial of Bruton’s tyrosine kinase inhibitor (PRN1008) in the treatment of canine pemphigus foliaceus
|Veterinary Dermatology|2020|26